Literature DB >> 27466465

Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis.

Yoshiki Sekijima1, Masahide Yazaki2, Kazuhiro Oguchi2, Naoki Ezawa2, Tsuneaki Yoshinaga2, Mitsunori Yamada2, Hiroyuki Yahikozawa2, Masahide Watanabe2, Fuyuki Kametani2, Shu-Ichi Ikeda2.   

Abstract

OBJECTIVE: To investigate the prevalence and clinical features of posttransplant CNS symptoms in patients with hereditary ATTR amyloidosis and their Pittsburgh compound B (PiB)-PET imaging correlates.
METHODS: We monitored prevalence and type of CNS symptoms in 53 consecutive posttransplant patients with hereditary ATTR amyloidosis. (11)C-PiB-PET was performed in 15 patients with various disease durations. We also analyzed pathologic and biochemical characteristics of ATTR amyloid deposition in the brain of a posttransplant patient.
RESULTS: Transient focal neurologic episodes (TFNEs) attributed to ATTR-type cerebral amyloid angiopathy (CAA) were found in 11.3% of posttransplant hereditary ATTR amyloidosis patients. TFNE occurred on average 16.8 years after onset of the disease. Patients with longer duration of illness (≥10 years) showed increased (11)C-PiB retention in the brain. The (11)C-PiB accumulation pattern in hereditary ATTR amyloidosis was unique and different from those in Alzheimer disease or Aβ-type CAA. In the autopsy case, ATTR amyloid deposition was mainly localized to leptomeningeal vessels and leptomeninges of the brain. Amyloid fibrils in the brain were almost completely composed of variant transthyretin (TTR).
CONCLUSIONS: TFNE due to ATTR-type CAA occurred frequently in posttransplant patients with long disease durations. (11)C-PiB-PET is a useful diagnostic tool for ATTR-type CAA. ATTR amyloid deposition in the CNS, as measured by PiB-PET, was detected approximately 10 years before onset of TFNE.
© 2016 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27466465     DOI: 10.1212/WNL.0000000000003001

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  Time for new imaging and therapeutic approaches in cardiac amyloidosis.

Authors:  Riemer H J A Slart; Andor W J M Glaudemans; Walter Noordzij; Johan Bijzet; Bouke P C Hazenberg; Hans L A Nienhuis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-23       Impact factor: 9.236

2.  Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis.

Authors:  Ana Martins da Silva; Sara Cavaco; Joana Fernandes; Raquel Samões; Cristina Alves; Márcio Cardoso; Jeffery W Kelly; Cecília Monteiro; Teresa Coelho
Journal:  J Neurol       Date:  2017-12-05       Impact factor: 4.849

3.  Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.

Authors:  Stephen Connelly; David E Mortenson; Sungwook Choi; Ian A Wilson; Evan T Powers; Jeffery W Kelly; Steven M Johnson
Journal:  Bioorg Med Chem Lett       Date:  2017-05-26       Impact factor: 2.823

4.  Relapsing polychondritis coupling with cerebral amyloid deposit inducing cerebral amyloid angiopathy-related inflammation.

Authors:  Kosuke Matsuzono; Kohei Furuya; Takeshi Igarashi; Akie Horikiri; Takamasa Murosaki; Daekwan Chi; Yuichi Toyama; Kumiko Miura; Tadashi Ozawa; Takafumi Mashiko; Haruo Shimazaki; Reiji Koide; Ryota Tanaka; Shigeru Fujimoto
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

5.  A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction.

Authors:  Xin Jiang; Richard Labaudinière; Joel N Buxbaum; Cecília Monteiro; Marta Novais; Teresa Coelho; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

6.  Amyloidosis of the Brain and Heart: Two Sides of the Same Coin?

Authors:  Chris L Schaich; Mathew S Maurer; Neelesh K Nadkarni
Journal:  JACC Heart Fail       Date:  2019-02       Impact factor: 12.035

7.  Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging.

Authors:  Naoki Ezawa; Nagaaki Katoh; Kazuhiro Oguchi; Tsuneaki Yoshinaga; Masahide Yazaki; Yoshiki Sekijima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-10       Impact factor: 9.236

8.  Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy.

Authors:  Jesús Romero-Imbroda; Teresa Sagrario-Fustero; Clementina Del Canto-Pérez
Journal:  J Clin Neurol       Date:  2017-09-04       Impact factor: 3.077

Review 9.  Transthyretin familial amyloid polyneuropathy: an update.

Authors:  Violaine Plante-Bordeneuve
Journal:  J Neurol       Date:  2017-12-16       Impact factor: 4.849

10.  Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients.

Authors:  Cecilia Monteiro; Ana Martins da Silva; Natália Ferreira; Jaleh Mesgarzadeh; Marta Novais; Teresa Coelho; Jeffery W Kelly
Journal:  Amyloid       Date:  2018-07-11       Impact factor: 7.141

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.